Dr George Morstyn has more than 25 years’ experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen. Dr Morstyn had overall responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen, and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn’s tenure. Prior to joining Amgen, Dr Morstyn was the principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors (CSFs). The CSFs were subsequently approved and launched, and were a major medical breakthrough that have been used to reduce side effects of chemotherapy and enable transplantation in more than 20 million patients worldwide. The CSFs have become multi-billion dollar drugs. Since returning to Australia, Dr Morstyn has been a non-executive director of various for-profit and not for profit companies, including many biotechs.
Dr Morstyn is a medical graduate of Monash University, and obtained a PhD at the Walter and Eliza Hall Institute and a FRACP in medical oncology following a fellowship at the National Cancer Institute in the US. He is currently on the Board of the CRC for Cancer Therapeutics, Symbio(Tokyo) and Biomedvic. He is a member of the Australian Institute of Company Directors and a Fellow of the Australian Academy of Technological Sciences and Engineering.« Back To Our Team